Assessment of potential transthyretin amyloid cardiomyopathy cases in the Brazilian public health system using a machine learning mode
PLos ONE
; 19(2): e0278738, fev.2024. ilus, tab
Article
in English
| CONASS, Sec. Est. Saúde SP, SESSP-IDPCPROD, Sec. Est. Saúde SP
| ID: biblio-1531135
Responsible library:
BR79.1
ABSTRACT
OBJECTIVES:
To identify and describe the profile of potential transthyretin cardiac amyloidosis (ATTR-CM) cases in the Brazilian public health system (SUS), using a predictive machine learning (ML) model.METHODS:
This was a retrospective descriptive database study that aimed to estimate the frequency of potential ATTR-CM cases in the Brazilian public health system using a supervised ML model, from January 2015 to December 2021. To build the model, a list of ICD-10 codes and procedures potentially related with ATTR-CM was created based on literature review and validated by experts.RESULTS:
From 2015 to 2021, the ML model classified 262 hereditary ATTR-CM (hATTR-CM) and 1,581 wild-type ATTR-CM (wtATTR-CM) potential cases. Overall, the median age of hATTR-CM and wtATTR-CM patients was 66.8 and 59.9 years, respectively. The ICD-10 codes most presented as hATTR-CM and wtATTR-CM were related to heart failure and arrythmias. Regarding the therapeutic itinerary, 13% and 5% of hATTR-CM and wtATTR-CM received treatment with tafamidis meglumine, respectively, while 0% and 29% of hATTR-CM and wtATTR-CM were referred to heart transplant.CONCLUSION:
Our findings may be useful to support the development of health guidelines and policies to improve diagnosis, treatment, and to cover unmet medical needs of patients with ATTR-CM in Brazil.
Full text:
Available
Collection:
National databases
/
Brazil
Database:
CONASS
/
Sec. Est. Saúde SP
/
SESSP-IDPCPROD
Main subject:
Amyloid Neuropathies
/
Cardiomyopathies
Limits:
Humans
Country/Region as subject:
South America
/
Brazil
Language:
English
Journal:
PLos ONE
Year:
2024
Document type:
Article
Institution/Affiliation country:
Heart Institute/BR
/
IQVIA Brazil/BR
/
IQVIA Brazil/US
/
Instituto Dante Pazzanese de Cardiologia/BR
/
Medical School of Ribeirão Preto/BR
/
Pfizer Brazil/BR
/
Pfizer Global/US